RNA, U6 small nuclear 1223, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-1223P profile across patient tissues and cancer cell-line models. RNU6-1223P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNU6-1223P is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, RNU6-1223P RNA expression shows 16,789 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, BLCA, and DLBC as cancer lineages where RNU6-1223P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-1223P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-1223P survival associations across molecular data types. RNU6-1223P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-1223P RNA expression–survival associations across cancer types. High RNU6-1223P expression shows unfavorable associations in ACC, MESO, LIHC and THCA, but favorable associations in HNSC and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RNU6-1223P RNA expression.
This table summarizes RNU6-1223P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-1223P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-1223P shows higher tumor expression in BLCA, READ, COAD, LUSC, LIHC and CHOL. The BLCA box plot shows higher RNU6-1223P RNA expression in tumor versus normal tissue (log2 FC = +0.709, t-test p = .005).
This table shows molecular features associated with RNU6-1223P in patient tissues and cancer cell lines. In patient samples, RNU6-1223P shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
